nodes	percent_of_prediction	percent_of_DWPC	metapath
Bisoprolol—Atenolol—Procarbazine—hematologic cancer	0.35	1	CrCrCtD
Bisoprolol—CYP2D6—Lomustine—hematologic cancer	0.0279	0.0738	CbGbCtD
Bisoprolol—CYP2D6—Idarubicin—hematologic cancer	0.0249	0.0658	CbGbCtD
Bisoprolol—CYP2D6—Hydroxyurea—hematologic cancer	0.0212	0.0559	CbGbCtD
Bisoprolol—CYP3A4—Bexarotene—hematologic cancer	0.0191	0.0505	CbGbCtD
Bisoprolol—CYP2D6—Bortezomib—hematologic cancer	0.0184	0.0487	CbGbCtD
Bisoprolol—CYP3A4—Lomustine—hematologic cancer	0.0178	0.0469	CbGbCtD
Bisoprolol—CYP3A4—Busulfan—hematologic cancer	0.0178	0.0469	CbGbCtD
Bisoprolol—CYP3A4—Thiotepa—hematologic cancer	0.0158	0.0418	CbGbCtD
Bisoprolol—CYP2D6—Imatinib—hematologic cancer	0.0135	0.0357	CbGbCtD
Bisoprolol—CYP3A4—Methoxsalen—hematologic cancer	0.0123	0.0325	CbGbCtD
Bisoprolol—CYP2D6—Nilotinib—hematologic cancer	0.0123	0.0324	CbGbCtD
Bisoprolol—CYP2D6—Vinorelbine—hematologic cancer	0.0122	0.0321	CbGbCtD
Bisoprolol—CYP3A4—Bortezomib—hematologic cancer	0.0117	0.0309	CbGbCtD
Bisoprolol—CYP3A4—Daunorubicin—hematologic cancer	0.0112	0.0296	CbGbCtD
Bisoprolol—CYP3A4—Cytarabine—hematologic cancer	0.00987	0.0261	CbGbCtD
Bisoprolol—CYP3A4—Teniposide—hematologic cancer	0.00973	0.0257	CbGbCtD
Bisoprolol—CYP3A4—Ifosfamide—hematologic cancer	0.00898	0.0237	CbGbCtD
Bisoprolol—CYP3A4—Imatinib—hematologic cancer	0.00857	0.0227	CbGbCtD
Bisoprolol—CYP3A4—Ruxolitinib—hematologic cancer	0.00807	0.0213	CbGbCtD
Bisoprolol—CYP3A4—Nilotinib—hematologic cancer	0.00779	0.0206	CbGbCtD
Bisoprolol—CYP3A4—Vinorelbine—hematologic cancer	0.00773	0.0204	CbGbCtD
Bisoprolol—CYP2D6—Vinblastine—hematologic cancer	0.00749	0.0198	CbGbCtD
Bisoprolol—CYP3A4—Triamcinolone—hematologic cancer	0.00707	0.0187	CbGbCtD
Bisoprolol—CYP3A4—Dasatinib—hematologic cancer	0.00689	0.0182	CbGbCtD
Bisoprolol—CYP3A4—Mitoxantrone—hematologic cancer	0.0068	0.018	CbGbCtD
Bisoprolol—CYP3A4—Betamethasone—hematologic cancer	0.00606	0.016	CbGbCtD
Bisoprolol—CYP3A4—Prednisolone—hematologic cancer	0.00598	0.0158	CbGbCtD
Bisoprolol—CYP3A4—Prednisone—hematologic cancer	0.00565	0.0149	CbGbCtD
Bisoprolol—CYP2D6—Dexamethasone—hematologic cancer	0.00555	0.0147	CbGbCtD
Bisoprolol—CYP3A4—Irinotecan—hematologic cancer	0.00536	0.0142	CbGbCtD
Bisoprolol—CYP3A4—Vinblastine—hematologic cancer	0.00476	0.0126	CbGbCtD
Bisoprolol—CYP3A4—Vincristine—hematologic cancer	0.00468	0.0124	CbGbCtD
Bisoprolol—CYP2D6—Doxorubicin—hematologic cancer	0.0046	0.0122	CbGbCtD
Bisoprolol—CYP3A4—Etoposide—hematologic cancer	0.00429	0.0113	CbGbCtD
Bisoprolol—CYP3A4—Dexamethasone—hematologic cancer	0.00353	0.00932	CbGbCtD
Bisoprolol—CYP3A4—Doxorubicin—hematologic cancer	0.00293	0.00774	CbGbCtD
Bisoprolol—Acebutolol—SLC22A1—hematologic cancer	0.000381	0.506	CrCbGaD
Bisoprolol—Atenolol—ABCB1—hematologic cancer	0.00012	0.16	CrCbGaD
Bisoprolol—Acebutolol—ABCB1—hematologic cancer	0.000111	0.147	CrCbGaD
Bisoprolol—Metoprolol—ABCB1—hematologic cancer	9.36e-05	0.124	CrCbGaD
Bisoprolol—Propranolol—ABCB1—hematologic cancer	4.72e-05	0.0627	CrCbGaD
Bisoprolol—Mediastinal disorder—Epirubicin—hematologic cancer	2.2e-05	8.96e-05	CcSEcCtD
Bisoprolol—Gastrointestinal disorder—Dexamethasone—hematologic cancer	2.2e-05	8.96e-05	CcSEcCtD
Bisoprolol—Gastrointestinal disorder—Betamethasone—hematologic cancer	2.2e-05	8.96e-05	CcSEcCtD
Bisoprolol—Back pain—Methotrexate—hematologic cancer	2.2e-05	8.95e-05	CcSEcCtD
Bisoprolol—Fatigue—Dexamethasone—hematologic cancer	2.2e-05	8.94e-05	CcSEcCtD
Bisoprolol—Fatigue—Betamethasone—hematologic cancer	2.2e-05	8.94e-05	CcSEcCtD
Bisoprolol—Pruritus—Etoposide—hematologic cancer	2.19e-05	8.92e-05	CcSEcCtD
Bisoprolol—Shock—Prednisone—hematologic cancer	2.19e-05	8.89e-05	CcSEcCtD
Bisoprolol—Arrhythmia—Epirubicin—hematologic cancer	2.18e-05	8.89e-05	CcSEcCtD
Bisoprolol—Pain—Dexamethasone—hematologic cancer	2.18e-05	8.87e-05	CcSEcCtD
Bisoprolol—Pain—Betamethasone—hematologic cancer	2.18e-05	8.87e-05	CcSEcCtD
Bisoprolol—Visual impairment—Doxorubicin—hematologic cancer	2.18e-05	8.87e-05	CcSEcCtD
Bisoprolol—Nervous system disorder—Prednisone—hematologic cancer	2.18e-05	8.86e-05	CcSEcCtD
Bisoprolol—Tachycardia—Prednisone—hematologic cancer	2.17e-05	8.82e-05	CcSEcCtD
Bisoprolol—Alopecia—Epirubicin—hematologic cancer	2.16e-05	8.79e-05	CcSEcCtD
Bisoprolol—Skin disorder—Prednisone—hematologic cancer	2.16e-05	8.78e-05	CcSEcCtD
Bisoprolol—Nausea—Gemcitabine—hematologic cancer	2.16e-05	8.77e-05	CcSEcCtD
Bisoprolol—Vomiting—Cisplatin—hematologic cancer	2.15e-05	8.75e-05	CcSEcCtD
Bisoprolol—Hyperhidrosis—Prednisone—hematologic cancer	2.15e-05	8.73e-05	CcSEcCtD
Bisoprolol—Mental disorder—Epirubicin—hematologic cancer	2.14e-05	8.71e-05	CcSEcCtD
Bisoprolol—Rash—Cisplatin—hematologic cancer	2.13e-05	8.68e-05	CcSEcCtD
Bisoprolol—Dermatitis—Cisplatin—hematologic cancer	2.13e-05	8.67e-05	CcSEcCtD
Bisoprolol—Erythema—Epirubicin—hematologic cancer	2.13e-05	8.66e-05	CcSEcCtD
Bisoprolol—Diarrhoea—Etoposide—hematologic cancer	2.12e-05	8.63e-05	CcSEcCtD
Bisoprolol—Eye disorder—Doxorubicin—hematologic cancer	2.11e-05	8.6e-05	CcSEcCtD
Bisoprolol—Ill-defined disorder—Methotrexate—hematologic cancer	2.11e-05	8.58e-05	CcSEcCtD
Bisoprolol—Tinnitus—Doxorubicin—hematologic cancer	2.11e-05	8.58e-05	CcSEcCtD
Bisoprolol—Feeling abnormal—Dexamethasone—hematologic cancer	2.1e-05	8.55e-05	CcSEcCtD
Bisoprolol—Feeling abnormal—Betamethasone—hematologic cancer	2.1e-05	8.55e-05	CcSEcCtD
Bisoprolol—Flushing—Doxorubicin—hematologic cancer	2.1e-05	8.54e-05	CcSEcCtD
Bisoprolol—Cardiac disorder—Doxorubicin—hematologic cancer	2.1e-05	8.54e-05	CcSEcCtD
Bisoprolol—Gastrointestinal pain—Dexamethasone—hematologic cancer	2.09e-05	8.48e-05	CcSEcCtD
Bisoprolol—Gastrointestinal pain—Betamethasone—hematologic cancer	2.09e-05	8.48e-05	CcSEcCtD
Bisoprolol—Dysgeusia—Epirubicin—hematologic cancer	2.08e-05	8.48e-05	CcSEcCtD
Bisoprolol—Hypersensitivity—Triamcinolone—hematologic cancer	2.07e-05	8.42e-05	CcSEcCtD
Bisoprolol—Back pain—Epirubicin—hematologic cancer	2.06e-05	8.38e-05	CcSEcCtD
Bisoprolol—Angiopathy—Doxorubicin—hematologic cancer	2.05e-05	8.35e-05	CcSEcCtD
Bisoprolol—Malaise—Methotrexate—hematologic cancer	2.05e-05	8.34e-05	CcSEcCtD
Bisoprolol—Dizziness—Etoposide—hematologic cancer	2.05e-05	8.34e-05	CcSEcCtD
Bisoprolol—Muscle spasms—Epirubicin—hematologic cancer	2.05e-05	8.32e-05	CcSEcCtD
Bisoprolol—Vertigo—Methotrexate—hematologic cancer	2.04e-05	8.31e-05	CcSEcCtD
Bisoprolol—Mediastinal disorder—Doxorubicin—hematologic cancer	2.04e-05	8.29e-05	CcSEcCtD
Bisoprolol—Urticaria—Dexamethasone—hematologic cancer	2.03e-05	8.24e-05	CcSEcCtD
Bisoprolol—Urticaria—Betamethasone—hematologic cancer	2.03e-05	8.24e-05	CcSEcCtD
Bisoprolol—Musculoskeletal discomfort—Prednisone—hematologic cancer	2.02e-05	8.23e-05	CcSEcCtD
Bisoprolol—Dizziness—Prednisolone—hematologic cancer	2.02e-05	8.22e-05	CcSEcCtD
Bisoprolol—Arrhythmia—Doxorubicin—hematologic cancer	2.02e-05	8.22e-05	CcSEcCtD
Bisoprolol—Asthenia—Triamcinolone—hematologic cancer	2.02e-05	8.2e-05	CcSEcCtD
Bisoprolol—Body temperature increased—Betamethasone—hematologic cancer	2.02e-05	8.2e-05	CcSEcCtD
Bisoprolol—Body temperature increased—Dexamethasone—hematologic cancer	2.02e-05	8.2e-05	CcSEcCtD
Bisoprolol—Abdominal pain—Dexamethasone—hematologic cancer	2.02e-05	8.2e-05	CcSEcCtD
Bisoprolol—Abdominal pain—Betamethasone—hematologic cancer	2.02e-05	8.2e-05	CcSEcCtD
Bisoprolol—Nausea—Cisplatin—hematologic cancer	2.01e-05	8.17e-05	CcSEcCtD
Bisoprolol—Insomnia—Prednisone—hematologic cancer	2.01e-05	8.17e-05	CcSEcCtD
Bisoprolol—Alopecia—Doxorubicin—hematologic cancer	2e-05	8.13e-05	CcSEcCtD
Bisoprolol—Paraesthesia—Prednisone—hematologic cancer	1.99e-05	8.11e-05	CcSEcCtD
Bisoprolol—Pruritus—Triamcinolone—hematologic cancer	1.99e-05	8.09e-05	CcSEcCtD
Bisoprolol—Cough—Methotrexate—hematologic cancer	1.98e-05	8.07e-05	CcSEcCtD
Bisoprolol—Mental disorder—Doxorubicin—hematologic cancer	1.98e-05	8.06e-05	CcSEcCtD
Bisoprolol—Ill-defined disorder—Epirubicin—hematologic cancer	1.97e-05	8.03e-05	CcSEcCtD
Bisoprolol—Vomiting—Etoposide—hematologic cancer	1.97e-05	8.02e-05	CcSEcCtD
Bisoprolol—Erythema—Doxorubicin—hematologic cancer	1.97e-05	8.01e-05	CcSEcCtD
Bisoprolol—Agitation—Epirubicin—hematologic cancer	1.96e-05	7.96e-05	CcSEcCtD
Bisoprolol—Dyspepsia—Prednisone—hematologic cancer	1.95e-05	7.95e-05	CcSEcCtD
Bisoprolol—Rash—Etoposide—hematologic cancer	1.95e-05	7.95e-05	CcSEcCtD
Bisoprolol—Dermatitis—Etoposide—hematologic cancer	1.95e-05	7.94e-05	CcSEcCtD
Bisoprolol—Headache—Etoposide—hematologic cancer	1.94e-05	7.9e-05	CcSEcCtD
Bisoprolol—Myalgia—Methotrexate—hematologic cancer	1.94e-05	7.88e-05	CcSEcCtD
Bisoprolol—Chest pain—Methotrexate—hematologic cancer	1.94e-05	7.88e-05	CcSEcCtD
Bisoprolol—Arthralgia—Methotrexate—hematologic cancer	1.94e-05	7.88e-05	CcSEcCtD
Bisoprolol—Dysgeusia—Doxorubicin—hematologic cancer	1.93e-05	7.85e-05	CcSEcCtD
Bisoprolol—Rash—Prednisolone—hematologic cancer	1.93e-05	7.84e-05	CcSEcCtD
Bisoprolol—Dermatitis—Prednisolone—hematologic cancer	1.93e-05	7.83e-05	CcSEcCtD
Bisoprolol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	1.92e-05	7.82e-05	CcSEcCtD
Bisoprolol—Malaise—Epirubicin—hematologic cancer	1.92e-05	7.81e-05	CcSEcCtD
Bisoprolol—Fatigue—Prednisone—hematologic cancer	1.91e-05	7.79e-05	CcSEcCtD
Bisoprolol—Headache—Prednisolone—hematologic cancer	1.91e-05	7.79e-05	CcSEcCtD
Bisoprolol—Discomfort—Methotrexate—hematologic cancer	1.91e-05	7.78e-05	CcSEcCtD
Bisoprolol—Vertigo—Epirubicin—hematologic cancer	1.91e-05	7.78e-05	CcSEcCtD
Bisoprolol—Syncope—Epirubicin—hematologic cancer	1.91e-05	7.76e-05	CcSEcCtD
Bisoprolol—Back pain—Doxorubicin—hematologic cancer	1.9e-05	7.75e-05	CcSEcCtD
Bisoprolol—Constipation—Prednisone—hematologic cancer	1.9e-05	7.73e-05	CcSEcCtD
Bisoprolol—Muscle spasms—Doxorubicin—hematologic cancer	1.89e-05	7.7e-05	CcSEcCtD
Bisoprolol—Palpitations—Epirubicin—hematologic cancer	1.88e-05	7.65e-05	CcSEcCtD
Bisoprolol—Confusional state—Methotrexate—hematologic cancer	1.87e-05	7.61e-05	CcSEcCtD
Bisoprolol—Loss of consciousness—Epirubicin—hematologic cancer	1.87e-05	7.61e-05	CcSEcCtD
Bisoprolol—Dizziness—Triamcinolone—hematologic cancer	1.86e-05	7.56e-05	CcSEcCtD
Bisoprolol—Cough—Epirubicin—hematologic cancer	1.86e-05	7.56e-05	CcSEcCtD
Bisoprolol—Infection—Methotrexate—hematologic cancer	1.84e-05	7.5e-05	CcSEcCtD
Bisoprolol—Nausea—Etoposide—hematologic cancer	1.84e-05	7.49e-05	CcSEcCtD
Bisoprolol—Feeling abnormal—Prednisone—hematologic cancer	1.83e-05	7.45e-05	CcSEcCtD
Bisoprolol—Asthenia—Dexamethasone—hematologic cancer	1.83e-05	7.44e-05	CcSEcCtD
Bisoprolol—Asthenia—Betamethasone—hematologic cancer	1.83e-05	7.44e-05	CcSEcCtD
Bisoprolol—Ill-defined disorder—Doxorubicin—hematologic cancer	1.83e-05	7.43e-05	CcSEcCtD
Bisoprolol—Nervous system disorder—Methotrexate—hematologic cancer	1.82e-05	7.41e-05	CcSEcCtD
Bisoprolol—Thrombocytopenia—Methotrexate—hematologic cancer	1.82e-05	7.39e-05	CcSEcCtD
Bisoprolol—Gastrointestinal pain—Prednisone—hematologic cancer	1.82e-05	7.39e-05	CcSEcCtD
Bisoprolol—Nausea—Prednisolone—hematologic cancer	1.82e-05	7.39e-05	CcSEcCtD
Bisoprolol—Chest pain—Epirubicin—hematologic cancer	1.81e-05	7.37e-05	CcSEcCtD
Bisoprolol—Arthralgia—Epirubicin—hematologic cancer	1.81e-05	7.37e-05	CcSEcCtD
Bisoprolol—Myalgia—Epirubicin—hematologic cancer	1.81e-05	7.37e-05	CcSEcCtD
Bisoprolol—Agitation—Doxorubicin—hematologic cancer	1.81e-05	7.36e-05	CcSEcCtD
Bisoprolol—Anxiety—Epirubicin—hematologic cancer	1.81e-05	7.35e-05	CcSEcCtD
Bisoprolol—Pruritus—Betamethasone—hematologic cancer	1.8e-05	7.34e-05	CcSEcCtD
Bisoprolol—Pruritus—Dexamethasone—hematologic cancer	1.8e-05	7.34e-05	CcSEcCtD
Bisoprolol—Skin disorder—Methotrexate—hematologic cancer	1.8e-05	7.33e-05	CcSEcCtD
Bisoprolol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	1.8e-05	7.32e-05	CcSEcCtD
Bisoprolol—Hyperhidrosis—Methotrexate—hematologic cancer	1.79e-05	7.3e-05	CcSEcCtD
Bisoprolol—Discomfort—Epirubicin—hematologic cancer	1.79e-05	7.28e-05	CcSEcCtD
Bisoprolol—Vomiting—Triamcinolone—hematologic cancer	1.79e-05	7.27e-05	CcSEcCtD
Bisoprolol—Malaise—Doxorubicin—hematologic cancer	1.78e-05	7.22e-05	CcSEcCtD
Bisoprolol—Rash—Triamcinolone—hematologic cancer	1.77e-05	7.21e-05	CcSEcCtD
Bisoprolol—Dry mouth—Epirubicin—hematologic cancer	1.77e-05	7.21e-05	CcSEcCtD
Bisoprolol—Dermatitis—Triamcinolone—hematologic cancer	1.77e-05	7.2e-05	CcSEcCtD
Bisoprolol—Vertigo—Doxorubicin—hematologic cancer	1.77e-05	7.2e-05	CcSEcCtD
Bisoprolol—Syncope—Doxorubicin—hematologic cancer	1.77e-05	7.18e-05	CcSEcCtD
Bisoprolol—Urticaria—Prednisone—hematologic cancer	1.76e-05	7.18e-05	CcSEcCtD
Bisoprolol—Headache—Triamcinolone—hematologic cancer	1.76e-05	7.16e-05	CcSEcCtD
Bisoprolol—Abdominal pain—Prednisone—hematologic cancer	1.76e-05	7.14e-05	CcSEcCtD
Bisoprolol—Body temperature increased—Prednisone—hematologic cancer	1.76e-05	7.14e-05	CcSEcCtD
Bisoprolol—Confusional state—Epirubicin—hematologic cancer	1.75e-05	7.13e-05	CcSEcCtD
Bisoprolol—Diarrhoea—Dexamethasone—hematologic cancer	1.74e-05	7.1e-05	CcSEcCtD
Bisoprolol—Diarrhoea—Betamethasone—hematologic cancer	1.74e-05	7.1e-05	CcSEcCtD
Bisoprolol—Palpitations—Doxorubicin—hematologic cancer	1.74e-05	7.08e-05	CcSEcCtD
Bisoprolol—Oedema—Epirubicin—hematologic cancer	1.74e-05	7.07e-05	CcSEcCtD
Bisoprolol—Hypotension—Methotrexate—hematologic cancer	1.73e-05	7.06e-05	CcSEcCtD
Bisoprolol—Loss of consciousness—Doxorubicin—hematologic cancer	1.73e-05	7.04e-05	CcSEcCtD
Bisoprolol—Infection—Epirubicin—hematologic cancer	1.73e-05	7.02e-05	CcSEcCtD
Bisoprolol—Cough—Doxorubicin—hematologic cancer	1.72e-05	6.99e-05	CcSEcCtD
Bisoprolol—Shock—Epirubicin—hematologic cancer	1.71e-05	6.95e-05	CcSEcCtD
Bisoprolol—Nervous system disorder—Epirubicin—hematologic cancer	1.7e-05	6.93e-05	CcSEcCtD
Bisoprolol—Thrombocytopenia—Epirubicin—hematologic cancer	1.7e-05	6.92e-05	CcSEcCtD
Bisoprolol—Tachycardia—Epirubicin—hematologic cancer	1.7e-05	6.9e-05	CcSEcCtD
Bisoprolol—Musculoskeletal discomfort—Methotrexate—hematologic cancer	1.69e-05	6.88e-05	CcSEcCtD
Bisoprolol—Skin disorder—Epirubicin—hematologic cancer	1.69e-05	6.86e-05	CcSEcCtD
Bisoprolol—Dizziness—Betamethasone—hematologic cancer	1.69e-05	6.86e-05	CcSEcCtD
Bisoprolol—Dizziness—Dexamethasone—hematologic cancer	1.69e-05	6.86e-05	CcSEcCtD
Bisoprolol—Hyperhidrosis—Epirubicin—hematologic cancer	1.68e-05	6.83e-05	CcSEcCtD
Bisoprolol—Insomnia—Methotrexate—hematologic cancer	1.68e-05	6.83e-05	CcSEcCtD
Bisoprolol—Chest pain—Doxorubicin—hematologic cancer	1.68e-05	6.82e-05	CcSEcCtD
Bisoprolol—Arthralgia—Doxorubicin—hematologic cancer	1.68e-05	6.82e-05	CcSEcCtD
Bisoprolol—Myalgia—Doxorubicin—hematologic cancer	1.68e-05	6.82e-05	CcSEcCtD
Bisoprolol—Anxiety—Doxorubicin—hematologic cancer	1.67e-05	6.8e-05	CcSEcCtD
Bisoprolol—Nausea—Triamcinolone—hematologic cancer	1.67e-05	6.79e-05	CcSEcCtD
Bisoprolol—Paraesthesia—Methotrexate—hematologic cancer	1.67e-05	6.78e-05	CcSEcCtD
Bisoprolol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	1.67e-05	6.77e-05	CcSEcCtD
Bisoprolol—Discomfort—Doxorubicin—hematologic cancer	1.66e-05	6.74e-05	CcSEcCtD
Bisoprolol—Dyspnoea—Methotrexate—hematologic cancer	1.65e-05	6.73e-05	CcSEcCtD
Bisoprolol—Somnolence—Methotrexate—hematologic cancer	1.65e-05	6.71e-05	CcSEcCtD
Bisoprolol—Dry mouth—Doxorubicin—hematologic cancer	1.64e-05	6.67e-05	CcSEcCtD
Bisoprolol—Hypersensitivity—Prednisone—hematologic cancer	1.64e-05	6.66e-05	CcSEcCtD
Bisoprolol—Dyspepsia—Methotrexate—hematologic cancer	1.63e-05	6.65e-05	CcSEcCtD
Bisoprolol—Hypotension—Epirubicin—hematologic cancer	1.62e-05	6.6e-05	CcSEcCtD
Bisoprolol—Vomiting—Betamethasone—hematologic cancer	1.62e-05	6.6e-05	CcSEcCtD
Bisoprolol—Vomiting—Dexamethasone—hematologic cancer	1.62e-05	6.6e-05	CcSEcCtD
Bisoprolol—Confusional state—Doxorubicin—hematologic cancer	1.62e-05	6.59e-05	CcSEcCtD
Bisoprolol—Rash—Betamethasone—hematologic cancer	1.61e-05	6.54e-05	CcSEcCtD
Bisoprolol—Rash—Dexamethasone—hematologic cancer	1.61e-05	6.54e-05	CcSEcCtD
Bisoprolol—Oedema—Doxorubicin—hematologic cancer	1.61e-05	6.54e-05	CcSEcCtD
Bisoprolol—Dermatitis—Betamethasone—hematologic cancer	1.61e-05	6.54e-05	CcSEcCtD
Bisoprolol—Dermatitis—Dexamethasone—hematologic cancer	1.61e-05	6.54e-05	CcSEcCtD
Bisoprolol—Gastrointestinal disorder—Methotrexate—hematologic cancer	1.6e-05	6.52e-05	CcSEcCtD
Bisoprolol—Fatigue—Methotrexate—hematologic cancer	1.6e-05	6.51e-05	CcSEcCtD
Bisoprolol—Headache—Betamethasone—hematologic cancer	1.6e-05	6.5e-05	CcSEcCtD
Bisoprolol—Headache—Dexamethasone—hematologic cancer	1.6e-05	6.5e-05	CcSEcCtD
Bisoprolol—Infection—Doxorubicin—hematologic cancer	1.6e-05	6.5e-05	CcSEcCtD
Bisoprolol—Asthenia—Prednisone—hematologic cancer	1.59e-05	6.48e-05	CcSEcCtD
Bisoprolol—Pain—Methotrexate—hematologic cancer	1.59e-05	6.46e-05	CcSEcCtD
Bisoprolol—Musculoskeletal discomfort—Epirubicin—hematologic cancer	1.58e-05	6.44e-05	CcSEcCtD
Bisoprolol—Shock—Doxorubicin—hematologic cancer	1.58e-05	6.43e-05	CcSEcCtD
Bisoprolol—Nervous system disorder—Doxorubicin—hematologic cancer	1.58e-05	6.41e-05	CcSEcCtD
Bisoprolol—Thrombocytopenia—Doxorubicin—hematologic cancer	1.57e-05	6.4e-05	CcSEcCtD
Bisoprolol—Pruritus—Prednisone—hematologic cancer	1.57e-05	6.39e-05	CcSEcCtD
Bisoprolol—Insomnia—Epirubicin—hematologic cancer	1.57e-05	6.39e-05	CcSEcCtD
Bisoprolol—Tachycardia—Doxorubicin—hematologic cancer	1.57e-05	6.38e-05	CcSEcCtD
Bisoprolol—Skin disorder—Doxorubicin—hematologic cancer	1.56e-05	6.35e-05	CcSEcCtD
Bisoprolol—Paraesthesia—Epirubicin—hematologic cancer	1.56e-05	6.35e-05	CcSEcCtD
Bisoprolol—Hyperhidrosis—Doxorubicin—hematologic cancer	1.55e-05	6.32e-05	CcSEcCtD
Bisoprolol—Dyspnoea—Epirubicin—hematologic cancer	1.55e-05	6.3e-05	CcSEcCtD
Bisoprolol—Somnolence—Epirubicin—hematologic cancer	1.54e-05	6.28e-05	CcSEcCtD
Bisoprolol—Feeling abnormal—Methotrexate—hematologic cancer	1.53e-05	6.22e-05	CcSEcCtD
Bisoprolol—Dyspepsia—Epirubicin—hematologic cancer	1.53e-05	6.22e-05	CcSEcCtD
Bisoprolol—Diarrhoea—Prednisone—hematologic cancer	1.52e-05	6.18e-05	CcSEcCtD
Bisoprolol—Gastrointestinal pain—Methotrexate—hematologic cancer	1.52e-05	6.17e-05	CcSEcCtD
Bisoprolol—Nausea—Dexamethasone—hematologic cancer	1.51e-05	6.16e-05	CcSEcCtD
Bisoprolol—Nausea—Betamethasone—hematologic cancer	1.51e-05	6.16e-05	CcSEcCtD
Bisoprolol—Hypotension—Doxorubicin—hematologic cancer	1.5e-05	6.11e-05	CcSEcCtD
Bisoprolol—Gastrointestinal disorder—Epirubicin—hematologic cancer	1.5e-05	6.1e-05	CcSEcCtD
Bisoprolol—Fatigue—Epirubicin—hematologic cancer	1.5e-05	6.09e-05	CcSEcCtD
Bisoprolol—Pain—Epirubicin—hematologic cancer	1.49e-05	6.04e-05	CcSEcCtD
Bisoprolol—Constipation—Epirubicin—hematologic cancer	1.49e-05	6.04e-05	CcSEcCtD
Bisoprolol—Urticaria—Methotrexate—hematologic cancer	1.47e-05	6e-05	CcSEcCtD
Bisoprolol—Dizziness—Prednisone—hematologic cancer	1.47e-05	5.97e-05	CcSEcCtD
Bisoprolol—Body temperature increased—Methotrexate—hematologic cancer	1.47e-05	5.97e-05	CcSEcCtD
Bisoprolol—Abdominal pain—Methotrexate—hematologic cancer	1.47e-05	5.97e-05	CcSEcCtD
Bisoprolol—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	1.46e-05	5.96e-05	CcSEcCtD
Bisoprolol—Insomnia—Doxorubicin—hematologic cancer	1.45e-05	5.91e-05	CcSEcCtD
Bisoprolol—Paraesthesia—Doxorubicin—hematologic cancer	1.44e-05	5.87e-05	CcSEcCtD
Bisoprolol—Dyspnoea—Doxorubicin—hematologic cancer	1.43e-05	5.83e-05	CcSEcCtD
Bisoprolol—Feeling abnormal—Epirubicin—hematologic cancer	1.43e-05	5.82e-05	CcSEcCtD
Bisoprolol—Somnolence—Doxorubicin—hematologic cancer	1.43e-05	5.81e-05	CcSEcCtD
Bisoprolol—Gastrointestinal pain—Epirubicin—hematologic cancer	1.42e-05	5.78e-05	CcSEcCtD
Bisoprolol—Dyspepsia—Doxorubicin—hematologic cancer	1.41e-05	5.76e-05	CcSEcCtD
Bisoprolol—Vomiting—Prednisone—hematologic cancer	1.41e-05	5.74e-05	CcSEcCtD
Bisoprolol—Rash—Prednisone—hematologic cancer	1.4e-05	5.7e-05	CcSEcCtD
Bisoprolol—Dermatitis—Prednisone—hematologic cancer	1.4e-05	5.69e-05	CcSEcCtD
Bisoprolol—Headache—Prednisone—hematologic cancer	1.39e-05	5.66e-05	CcSEcCtD
Bisoprolol—Gastrointestinal disorder—Doxorubicin—hematologic cancer	1.39e-05	5.64e-05	CcSEcCtD
Bisoprolol—Fatigue—Doxorubicin—hematologic cancer	1.39e-05	5.64e-05	CcSEcCtD
Bisoprolol—Urticaria—Epirubicin—hematologic cancer	1.38e-05	5.61e-05	CcSEcCtD
Bisoprolol—Pain—Doxorubicin—hematologic cancer	1.37e-05	5.59e-05	CcSEcCtD
Bisoprolol—Constipation—Doxorubicin—hematologic cancer	1.37e-05	5.59e-05	CcSEcCtD
Bisoprolol—Body temperature increased—Epirubicin—hematologic cancer	1.37e-05	5.59e-05	CcSEcCtD
Bisoprolol—Abdominal pain—Epirubicin—hematologic cancer	1.37e-05	5.59e-05	CcSEcCtD
Bisoprolol—Hypersensitivity—Methotrexate—hematologic cancer	1.37e-05	5.56e-05	CcSEcCtD
Bisoprolol—Asthenia—Methotrexate—hematologic cancer	1.33e-05	5.42e-05	CcSEcCtD
Bisoprolol—Feeling abnormal—Doxorubicin—hematologic cancer	1.32e-05	5.39e-05	CcSEcCtD
Bisoprolol—Nausea—Prednisone—hematologic cancer	1.32e-05	5.37e-05	CcSEcCtD
Bisoprolol—Gastrointestinal pain—Doxorubicin—hematologic cancer	1.31e-05	5.35e-05	CcSEcCtD
Bisoprolol—Pruritus—Methotrexate—hematologic cancer	1.31e-05	5.34e-05	CcSEcCtD
Bisoprolol—Hypersensitivity—Epirubicin—hematologic cancer	1.28e-05	5.21e-05	CcSEcCtD
Bisoprolol—Urticaria—Doxorubicin—hematologic cancer	1.28e-05	5.19e-05	CcSEcCtD
Bisoprolol—Abdominal pain—Doxorubicin—hematologic cancer	1.27e-05	5.17e-05	CcSEcCtD
Bisoprolol—Body temperature increased—Doxorubicin—hematologic cancer	1.27e-05	5.17e-05	CcSEcCtD
Bisoprolol—Diarrhoea—Methotrexate—hematologic cancer	1.27e-05	5.17e-05	CcSEcCtD
Bisoprolol—Asthenia—Epirubicin—hematologic cancer	1.25e-05	5.07e-05	CcSEcCtD
Bisoprolol—Pruritus—Epirubicin—hematologic cancer	1.23e-05	5e-05	CcSEcCtD
Bisoprolol—Dizziness—Methotrexate—hematologic cancer	1.23e-05	4.99e-05	CcSEcCtD
Bisoprolol—Diarrhoea—Epirubicin—hematologic cancer	1.19e-05	4.83e-05	CcSEcCtD
Bisoprolol—Hypersensitivity—Doxorubicin—hematologic cancer	1.18e-05	4.82e-05	CcSEcCtD
Bisoprolol—Vomiting—Methotrexate—hematologic cancer	1.18e-05	4.8e-05	CcSEcCtD
Bisoprolol—Rash—Methotrexate—hematologic cancer	1.17e-05	4.76e-05	CcSEcCtD
Bisoprolol—Dermatitis—Methotrexate—hematologic cancer	1.17e-05	4.76e-05	CcSEcCtD
Bisoprolol—Headache—Methotrexate—hematologic cancer	1.16e-05	4.73e-05	CcSEcCtD
Bisoprolol—Asthenia—Doxorubicin—hematologic cancer	1.15e-05	4.69e-05	CcSEcCtD
Bisoprolol—Dizziness—Epirubicin—hematologic cancer	1.15e-05	4.67e-05	CcSEcCtD
Bisoprolol—Pruritus—Doxorubicin—hematologic cancer	1.14e-05	4.63e-05	CcSEcCtD
Bisoprolol—Vomiting—Epirubicin—hematologic cancer	1.1e-05	4.49e-05	CcSEcCtD
Bisoprolol—Nausea—Methotrexate—hematologic cancer	1.1e-05	4.49e-05	CcSEcCtD
Bisoprolol—Diarrhoea—Doxorubicin—hematologic cancer	1.1e-05	4.47e-05	CcSEcCtD
Bisoprolol—Rash—Epirubicin—hematologic cancer	1.1e-05	4.46e-05	CcSEcCtD
Bisoprolol—Dermatitis—Epirubicin—hematologic cancer	1.09e-05	4.45e-05	CcSEcCtD
Bisoprolol—Headache—Epirubicin—hematologic cancer	1.09e-05	4.43e-05	CcSEcCtD
Bisoprolol—Dizziness—Doxorubicin—hematologic cancer	1.06e-05	4.32e-05	CcSEcCtD
Bisoprolol—Nausea—Epirubicin—hematologic cancer	1.03e-05	4.2e-05	CcSEcCtD
Bisoprolol—Vomiting—Doxorubicin—hematologic cancer	1.02e-05	4.16e-05	CcSEcCtD
Bisoprolol—Rash—Doxorubicin—hematologic cancer	1.01e-05	4.12e-05	CcSEcCtD
Bisoprolol—Dermatitis—Doxorubicin—hematologic cancer	1.01e-05	4.12e-05	CcSEcCtD
Bisoprolol—Headache—Doxorubicin—hematologic cancer	1.01e-05	4.1e-05	CcSEcCtD
Bisoprolol—Nausea—Doxorubicin—hematologic cancer	9.55e-06	3.88e-05	CcSEcCtD
Bisoprolol—CYP2D6—Metabolism—SPHK1—hematologic cancer	6.97e-06	0.000273	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—STAT1—hematologic cancer	6.94e-06	0.000272	CbGpPWpGaD
Bisoprolol—ADRB1—GPCR downstream signaling—PIK3R1—hematologic cancer	6.89e-06	0.00027	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—CCL2—hematologic cancer	6.87e-06	0.000269	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—IL6R—hematologic cancer	6.85e-06	0.000269	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR downstream signaling—PIK3R1—hematologic cancer	6.74e-06	0.000264	CbGpPWpGaD
Bisoprolol—ADRB1—GPCR downstream signaling—JAK2—hematologic cancer	6.7e-06	0.000263	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—UGT1A1—hematologic cancer	6.69e-06	0.000262	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—MAP2K1—hematologic cancer	6.67e-06	0.000262	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—GRB2—hematologic cancer	6.64e-06	0.00026	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—PIK3CD—hematologic cancer	6.63e-06	0.00026	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—PDGFA—hematologic cancer	6.62e-06	0.00026	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—MTAP—hematologic cancer	6.6e-06	0.000259	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR downstream signaling—JAK2—hematologic cancer	6.55e-06	0.000257	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—KITLG—hematologic cancer	6.53e-06	0.000256	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—MAP2K1—hematologic cancer	6.53e-06	0.000256	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—SLC22A1—hematologic cancer	6.51e-06	0.000255	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—CRABP1—hematologic cancer	6.51e-06	0.000255	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—GRB2—hematologic cancer	6.5e-06	0.000255	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—PIK3CD—hematologic cancer	6.49e-06	0.000254	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—PDGFA—hematologic cancer	6.48e-06	0.000254	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—KITLG—hematologic cancer	6.39e-06	0.00025	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—STAT5A—hematologic cancer	6.38e-06	0.00025	CbGpPWpGaD
Bisoprolol—ADRB1—GPCR downstream signaling—PIK3CB—hematologic cancer	6.36e-06	0.000249	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—ALOX5—hematologic cancer	6.34e-06	0.000249	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CDKN2B—hematologic cancer	6.33e-06	0.000248	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—PIK3R1—hematologic cancer	6.26e-06	0.000245	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—STAT5A—hematologic cancer	6.24e-06	0.000245	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR downstream signaling—PIK3CB—hematologic cancer	6.23e-06	0.000244	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CDKN2B—hematologic cancer	6.19e-06	0.000243	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—NUP98—hematologic cancer	6.14e-06	0.000241	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—PIK3R1—hematologic cancer	6.12e-06	0.00024	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CD86—hematologic cancer	6.12e-06	0.00024	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—JAK2—hematologic cancer	6.08e-06	0.000239	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—HES1—hematologic cancer	6.03e-06	0.000237	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—NCOR1—hematologic cancer	6e-06	0.000235	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CD86—hematologic cancer	5.99e-06	0.000235	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—ADCY7—hematologic cancer	5.96e-06	0.000234	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—NCOA3—hematologic cancer	5.96e-06	0.000234	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—JAK2—hematologic cancer	5.95e-06	0.000233	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—FGF1—hematologic cancer	5.93e-06	0.000233	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CSF2—hematologic cancer	5.93e-06	0.000233	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—NUP214—hematologic cancer	5.92e-06	0.000232	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—HES1—hematologic cancer	5.9e-06	0.000231	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—FHL2—hematologic cancer	5.89e-06	0.000231	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—NCOR1—hematologic cancer	5.87e-06	0.00023	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—FOXO1—hematologic cancer	5.85e-06	0.000229	CbGpPWpGaD
Bisoprolol—ADRB1—GPCR downstream signaling—IL2—hematologic cancer	5.84e-06	0.000229	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—PDGFRB—hematologic cancer	5.84e-06	0.000229	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CSF2—hematologic cancer	5.8e-06	0.000228	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—FGF1—hematologic cancer	5.8e-06	0.000228	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—MTR—hematologic cancer	5.8e-06	0.000227	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—ABCG2—hematologic cancer	5.8e-06	0.000227	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—PIK3CB—hematologic cancer	5.78e-06	0.000227	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—AGRN—hematologic cancer	5.77e-06	0.000226	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—PDGFRA—hematologic cancer	5.75e-06	0.000225	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—JAK1—hematologic cancer	5.73e-06	0.000224	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—PRKCG—hematologic cancer	5.73e-06	0.000224	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—FOXO1—hematologic cancer	5.72e-06	0.000224	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR downstream signaling—IL2—hematologic cancer	5.72e-06	0.000224	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—PDGFRB—hematologic cancer	5.71e-06	0.000224	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—ENO2—hematologic cancer	5.69e-06	0.000223	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—PIK3CB—hematologic cancer	5.65e-06	0.000222	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—PDGFRA—hematologic cancer	5.62e-06	0.00022	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—JAK1—hematologic cancer	5.6e-06	0.00022	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—PRKCG—hematologic cancer	5.6e-06	0.00022	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—GSTT1—hematologic cancer	5.52e-06	0.000216	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—HMMR—hematologic cancer	5.47e-06	0.000215	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—IDH2—hematologic cancer	5.47e-06	0.000215	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—SDC1—hematologic cancer	5.39e-06	0.000211	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—IL2RA—hematologic cancer	5.35e-06	0.00021	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—IL2—hematologic cancer	5.31e-06	0.000208	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—TERT—hematologic cancer	5.29e-06	0.000207	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—IL2RA—hematologic cancer	5.23e-06	0.000205	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—IL2—hematologic cancer	5.19e-06	0.000204	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—TERT—hematologic cancer	5.17e-06	0.000203	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—PDGFB—hematologic cancer	5.16e-06	0.000202	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—ARNTL—hematologic cancer	5.15e-06	0.000202	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—PDGFB—hematologic cancer	5.05e-06	0.000198	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—TSC2—hematologic cancer	5.04e-06	0.000198	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—CA9—hematologic cancer	5.01e-06	0.000196	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—ACP5—hematologic cancer	5.01e-06	0.000196	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—NCOR2—hematologic cancer	4.94e-06	0.000194	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—TSC2—hematologic cancer	4.93e-06	0.000193	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—FGFR3—hematologic cancer	4.85e-06	0.00019	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—MAPK14—hematologic cancer	4.8e-06	0.000188	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—FGFR3—hematologic cancer	4.75e-06	0.000186	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—ESR1—hematologic cancer	4.71e-06	0.000185	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—IDH1—hematologic cancer	4.71e-06	0.000184	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—MAPK14—hematologic cancer	4.7e-06	0.000184	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—FN1—hematologic cancer	4.66e-06	0.000183	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—ABCC3—hematologic cancer	4.65e-06	0.000182	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—TXN—hematologic cancer	4.65e-06	0.000182	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—GSTO1—hematologic cancer	4.65e-06	0.000182	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—ESR1—hematologic cancer	4.61e-06	0.000181	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—NFKBIA—hematologic cancer	4.6e-06	0.00018	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—BAD—hematologic cancer	4.6e-06	0.00018	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—CD44—hematologic cancer	4.59e-06	0.00018	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—NQO1—hematologic cancer	4.59e-06	0.00018	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—NOTCH1—hematologic cancer	4.56e-06	0.000179	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—FN1—hematologic cancer	4.55e-06	0.000179	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—SPHK1—hematologic cancer	4.55e-06	0.000179	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—BAD—hematologic cancer	4.5e-06	0.000176	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—NFKBIA—hematologic cancer	4.5e-06	0.000176	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CD80—hematologic cancer	4.46e-06	0.000175	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—NOTCH1—hematologic cancer	4.46e-06	0.000175	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—KIT—hematologic cancer	4.46e-06	0.000175	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—PIK3CG—hematologic cancer	4.46e-06	0.000175	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—NRAS—hematologic cancer	4.46e-06	0.000175	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—PTPN11—hematologic cancer	4.38e-06	0.000172	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—UGT1A1—hematologic cancer	4.38e-06	0.000172	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CD80—hematologic cancer	4.37e-06	0.000171	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—KIT—hematologic cancer	4.36e-06	0.000171	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—PIK3CG—hematologic cancer	4.36e-06	0.000171	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—NRAS—hematologic cancer	4.36e-06	0.000171	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—CYCS—hematologic cancer	4.34e-06	0.00017	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	4.31e-06	0.000169	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—PTPN11—hematologic cancer	4.28e-06	0.000168	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—MAPK3—hematologic cancer	4.27e-06	0.000167	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—SLC22A1—hematologic cancer	4.26e-06	0.000167	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—CRABP1—hematologic cancer	4.26e-06	0.000167	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CREB1—hematologic cancer	4.24e-06	0.000166	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—BRAF—hematologic cancer	4.19e-06	0.000164	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—MAPK3—hematologic cancer	4.17e-06	0.000164	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CCL2—hematologic cancer	4.15e-06	0.000163	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CREB1—hematologic cancer	4.15e-06	0.000163	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—ALOX5—hematologic cancer	4.15e-06	0.000163	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—IL6R—hematologic cancer	4.14e-06	0.000162	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CREBBP—hematologic cancer	4.13e-06	0.000162	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—BRAF—hematologic cancer	4.1e-06	0.000161	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CCL2—hematologic cancer	4.06e-06	0.000159	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—IL6R—hematologic cancer	4.05e-06	0.000159	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CREBBP—hematologic cancer	4.04e-06	0.000158	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—NUP98—hematologic cancer	4.02e-06	0.000157	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—MAP2K1—hematologic cancer	3.94e-06	0.000155	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—PIK3CD—hematologic cancer	3.92e-06	0.000154	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—ADCY7—hematologic cancer	3.9e-06	0.000153	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—NCOA3—hematologic cancer	3.9e-06	0.000153	CbGpPWpGaD
Bisoprolol—ADRB1—GPCR downstream signaling—PIK3CA—hematologic cancer	3.88e-06	0.000152	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—NUP214—hematologic cancer	3.87e-06	0.000152	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—MAP2K1—hematologic cancer	3.86e-06	0.000151	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—KRAS—hematologic cancer	3.83e-06	0.00015	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—PIK3CD—hematologic cancer	3.83e-06	0.00015	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—GSTP1—hematologic cancer	3.83e-06	0.00015	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR downstream signaling—PIK3CA—hematologic cancer	3.8e-06	0.000149	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—ABCG2—hematologic cancer	3.79e-06	0.000149	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—MTR—hematologic cancer	3.79e-06	0.000149	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—KRAS—hematologic cancer	3.75e-06	0.000147	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—FGF2—hematologic cancer	3.75e-06	0.000147	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—ENO2—hematologic cancer	3.72e-06	0.000146	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—PIK3R1—hematologic cancer	3.7e-06	0.000145	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—FGF2—hematologic cancer	3.67e-06	0.000144	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—ABCB1—hematologic cancer	3.62e-06	0.000142	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—PIK3R1—hematologic cancer	3.62e-06	0.000142	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—GSTT1—hematologic cancer	3.61e-06	0.000141	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—JAK2—hematologic cancer	3.59e-06	0.000141	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—SDC1—hematologic cancer	3.53e-06	0.000138	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—PIK3CA—hematologic cancer	3.52e-06	0.000138	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—JAK2—hematologic cancer	3.52e-06	0.000138	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—GSTM1—hematologic cancer	3.52e-06	0.000138	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—NCOR1—hematologic cancer	3.52e-06	0.000138	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—MDM2—hematologic cancer	3.51e-06	0.000138	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—PIK3CA—hematologic cancer	3.45e-06	0.000135	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—MDM2—hematologic cancer	3.43e-06	0.000135	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—PIK3CB—hematologic cancer	3.41e-06	0.000134	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—MTOR—hematologic cancer	3.41e-06	0.000134	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—MTOR—hematologic cancer	3.34e-06	0.000131	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—PIK3CB—hematologic cancer	3.34e-06	0.000131	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—HRAS—hematologic cancer	3.26e-06	0.000128	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CDKN1B—hematologic cancer	3.2e-06	0.000126	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—HRAS—hematologic cancer	3.19e-06	0.000125	CbGpPWpGaD
Bisoprolol—ADRB1—GPCR downstream signaling—AKT1—hematologic cancer	3.17e-06	0.000124	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CASP3—hematologic cancer	3.14e-06	0.000123	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—IL2—hematologic cancer	3.14e-06	0.000123	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CDKN1B—hematologic cancer	3.13e-06	0.000123	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—IL6—hematologic cancer	3.12e-06	0.000122	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—MTHFR—hematologic cancer	3.11e-06	0.000122	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR downstream signaling—AKT1—hematologic cancer	3.1e-06	0.000122	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CASP3—hematologic cancer	3.07e-06	0.00012	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—IL2—hematologic cancer	3.07e-06	0.00012	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CCND1—hematologic cancer	3.06e-06	0.00012	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—IL6—hematologic cancer	3.05e-06	0.00012	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—JUN—hematologic cancer	3.05e-06	0.00012	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—CD44—hematologic cancer	3e-06	0.000118	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—NQO1—hematologic cancer	3e-06	0.000118	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CCND1—hematologic cancer	2.99e-06	0.000117	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—JUN—hematologic cancer	2.98e-06	0.000117	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CDKN1A—hematologic cancer	2.96e-06	0.000116	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—PTEN—hematologic cancer	2.95e-06	0.000116	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CDKN1A—hematologic cancer	2.89e-06	0.000113	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—MAPK8—hematologic cancer	2.89e-06	0.000113	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—PTEN—hematologic cancer	2.89e-06	0.000113	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—AKT1—hematologic cancer	2.88e-06	0.000113	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—CYCS—hematologic cancer	2.84e-06	0.000111	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—MAPK8—hematologic cancer	2.82e-06	0.000111	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	2.82e-06	0.000111	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—AKT1—hematologic cancer	2.82e-06	0.00011	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—EP300—hematologic cancer	2.81e-06	0.00011	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—EP300—hematologic cancer	2.75e-06	0.000108	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—SRC—hematologic cancer	2.74e-06	0.000107	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—SRC—hematologic cancer	2.68e-06	0.000105	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—VEGFA—hematologic cancer	2.66e-06	0.000104	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—STAT3—hematologic cancer	2.64e-06	0.000103	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—NRAS—hematologic cancer	2.63e-06	0.000103	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—PIK3CG—hematologic cancer	2.61e-06	0.000102	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—VEGFA—hematologic cancer	2.61e-06	0.000102	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—STAT3—hematologic cancer	2.58e-06	0.000101	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—NRAS—hematologic cancer	2.57e-06	0.000101	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—MAPK3—hematologic cancer	2.52e-06	9.88e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—GSTP1—hematologic cancer	2.5e-06	9.8e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—MAPK3—hematologic cancer	2.47e-06	9.67e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—MYC—hematologic cancer	2.45e-06	9.61e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—TGFB1—hematologic cancer	2.45e-06	9.59e-05	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—CREBBP—hematologic cancer	2.42e-06	9.49e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—MYC—hematologic cancer	2.4e-06	9.4e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—TGFB1—hematologic cancer	2.39e-06	9.38e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—ABCB1—hematologic cancer	2.37e-06	9.28e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—GSTM1—hematologic cancer	2.3e-06	9.01e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—NCOR1—hematologic cancer	2.3e-06	9.01e-05	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—PIK3CD—hematologic cancer	2.29e-06	9e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—KRAS—hematologic cancer	2.27e-06	8.88e-05	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—ALB—hematologic cancer	2.27e-06	8.88e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—KRAS—hematologic cancer	2.22e-06	8.69e-05	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—PIK3R1—hematologic cancer	2.17e-06	8.49e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—PIK3CA—hematologic cancer	2.08e-06	8.16e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—PIK3CA—hematologic cancer	2.04e-06	7.98e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—MTHFR—hematologic cancer	2.03e-06	7.96e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—TP53—hematologic cancer	2.01e-06	7.89e-05	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—PIK3CB—hematologic cancer	2e-06	7.84e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—TP53—hematologic cancer	1.97e-06	7.72e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—HRAS—hematologic cancer	1.93e-06	7.55e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—HRAS—hematologic cancer	1.88e-06	7.38e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—IL6—hematologic cancer	1.84e-06	7.22e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—IL6—hematologic cancer	1.8e-06	7.07e-05	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—PTEN—hematologic cancer	1.73e-06	6.78e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PIK3CG—hematologic cancer	1.71e-06	6.69e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—AKT1—hematologic cancer	1.7e-06	6.66e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—AKT1—hematologic cancer	1.66e-06	6.52e-05	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—EP300—hematologic cancer	1.65e-06	6.46e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—CREBBP—hematologic cancer	1.58e-06	6.2e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PIK3CD—hematologic cancer	1.5e-06	5.88e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—ALB—hematologic cancer	1.48e-06	5.81e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PIK3R1—hematologic cancer	1.42e-06	5.55e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PIK3CB—hematologic cancer	1.31e-06	5.13e-05	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—PIK3CA—hematologic cancer	1.22e-06	4.78e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PTEN—hematologic cancer	1.13e-06	4.43e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—EP300—hematologic cancer	1.08e-06	4.22e-05	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—AKT1—hematologic cancer	9.96e-07	3.9e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PIK3CA—hematologic cancer	7.97e-07	3.13e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—AKT1—hematologic cancer	6.51e-07	2.55e-05	CbGpPWpGaD
